Tags

Type your tag names separated by a space and hit enter

A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children.
Acta Anaesthesiol Scand. 2017 Apr; 61(4):374-380.AA

Abstract

BACKGROUND

Sugammadex is designed to be a reversal agent for steroidal muscle relaxants. The current trial was aimed to compare between sugammadex and neostigmine concerning the recovery time from neuromuscular blockade. We hypothesised that sugammadex might have shorter recovery time than neostigmine.

METHODS

Sixty paediatric patients aged 2-10 years scheduled for lower abdominal surgeries were randomly assigned into two equal groups to receive 4 mg/kg sugammadex (Group S) or 0.35 mg/kg neostigmine and 0.02 mg/kg atropine (Group N) as a reversal agent for rocuronium at the end of surgery. Primary outcome was the recovery time [time from starting of sugammadex or neostigmine till reaching train of four (TOF) ratio> 0.9] whereas secondary outcomes included number of patients who needed another dose of sugammadex or neostigmine to reach TOF ratio> 0.9, extubation time (time from stoppage of anaesthetic inhalation until the patient fulfilled criteria for safe extubation, post-anaesthesia care unit (PACU) discharge time and post-operative adverse effects.

RESULTS

The mean recovery and extubation times were significantly shorter (P = 0.002 and 0.005) in Group S compared with Group N (2.5 and 2.0 min vs. 12.6 min and 4.3 min respectively). In the Group N, eight patients needed another reversal dose compared with one patient in Group S (P = 0.035). PACU discharge time showed no significant difference between both groups. Incidence of nausea, vomiting, tachycardia, and dry mouth were significantly higher in Group N.

CONCLUSION

Sugammadex administration in children resulted in faster recovery and extubation times and lower incidence of adverse events compared with neostigmine.

Authors+Show Affiliations

Faculty of Medicine, Minoufiya University, Minoufiya, Egypt.Faculty of Medicine, Minoufiya University, Minoufiya, Egypt.Faculty of Medicine, Minoufiya University, Minoufiya, Egypt.

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

28185260

Citation

Ammar, A S., et al. "A Comparison of Sugammadex and Neostigmine for Reversal of Rocuronium-induced Neuromuscular Blockade in Children." Acta Anaesthesiologica Scandinavica, vol. 61, no. 4, 2017, pp. 374-380.
Ammar AS, Mahmoud KM, Kasemy ZA. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. Acta Anaesthesiol Scand. 2017;61(4):374-380.
Ammar, A. S., Mahmoud, K. M., & Kasemy, Z. A. (2017). A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. Acta Anaesthesiologica Scandinavica, 61(4), 374-380. https://doi.org/10.1111/aas.12868
Ammar AS, Mahmoud KM, Kasemy ZA. A Comparison of Sugammadex and Neostigmine for Reversal of Rocuronium-induced Neuromuscular Blockade in Children. Acta Anaesthesiol Scand. 2017;61(4):374-380. PubMed PMID: 28185260.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. AU - Ammar,A S, AU - Mahmoud,K M, AU - Kasemy,Z A, Y1 - 2017/02/10/ PY - 2016/08/22/received PY - 2017/01/15/revised PY - 2017/01/16/accepted PY - 2017/2/12/pubmed PY - 2017/3/16/medline PY - 2017/2/11/entrez SP - 374 EP - 380 JF - Acta anaesthesiologica Scandinavica JO - Acta Anaesthesiol Scand VL - 61 IS - 4 N2 - BACKGROUND: Sugammadex is designed to be a reversal agent for steroidal muscle relaxants. The current trial was aimed to compare between sugammadex and neostigmine concerning the recovery time from neuromuscular blockade. We hypothesised that sugammadex might have shorter recovery time than neostigmine. METHODS: Sixty paediatric patients aged 2-10 years scheduled for lower abdominal surgeries were randomly assigned into two equal groups to receive 4 mg/kg sugammadex (Group S) or 0.35 mg/kg neostigmine and 0.02 mg/kg atropine (Group N) as a reversal agent for rocuronium at the end of surgery. Primary outcome was the recovery time [time from starting of sugammadex or neostigmine till reaching train of four (TOF) ratio> 0.9] whereas secondary outcomes included number of patients who needed another dose of sugammadex or neostigmine to reach TOF ratio> 0.9, extubation time (time from stoppage of anaesthetic inhalation until the patient fulfilled criteria for safe extubation, post-anaesthesia care unit (PACU) discharge time and post-operative adverse effects. RESULTS: The mean recovery and extubation times were significantly shorter (P = 0.002 and 0.005) in Group S compared with Group N (2.5 and 2.0 min vs. 12.6 min and 4.3 min respectively). In the Group N, eight patients needed another reversal dose compared with one patient in Group S (P = 0.035). PACU discharge time showed no significant difference between both groups. Incidence of nausea, vomiting, tachycardia, and dry mouth were significantly higher in Group N. CONCLUSION: Sugammadex administration in children resulted in faster recovery and extubation times and lower incidence of adverse events compared with neostigmine. SN - 1399-6576 UR - https://www.unboundmedicine.com/medline/citation/28185260/A_comparison_of_sugammadex_and_neostigmine_for_reversal_of_rocuronium_induced_neuromuscular_blockade_in_children_ L2 - https://doi.org/10.1111/aas.12868 DB - PRIME DP - Unbound Medicine ER -